CDK4 and breast carcinoma: In “The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?”, Giraudo et al. reviewed the key study results from adjuvant ribociclib (NATALEE)- and abemaciclib (monarchE)-related landmark studies [1,2,3].